Complement-mediated Hemolytic Anemias, An Issue of Hematology/Oncology Clinics of North America

Robert A. Brodsky

Description

This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Robert Brodsky, is devoted to Complement-mediated Hemolytic Anemias. Articles in this outstanding issue include: Complement: An overview for the clinician; Warm autoimmune hemolytic anemia; Cold Agglutinin Disease; ABO incompatible blood transfusions; Paroxysmal cold hemoglobinuria; Paroxysmal nocturnal hemoglobinuria; Congenital CD59 deficiency; Atypical Hemolytic Uremic Syndrome (HUS); Typical Hemolytic Uremic Syndrome (HUS); Thrombotic thrombocytopenic purpura; and Pharmacologic complement inhibitors.

Sujets

• Médecine
• Médecine Générale
• Medical
• Hermatology

Informations

• Publié par: Elsevier
• Date de parution: 20 octobre 2015
• Nombre de lectures: 0
• EAN13: 9780323388917
• Langue: English
• Poids de l'ouvrage: 3 Mo

Extrait

Clinics Review Articles HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA
Complement-Mediated Hemolytic Anemias

Robert A. Brodsky, MD
Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
ISSN  0889-8588 Volume 29 • Number 3 • June 2015
Elsevier
Table of Contents
Cover image
Title page
Copyright
Contributors
Consulting Editors
Editor
Authors
Forthcoming Issues
Forthcoming Issues
Recent Issues
Preface: Complement in Health and Disease
Complement
Key points
Activation of the complement system
Regulation of the complement system
Functions of the complement system
Hemolysis from ABO Incompatibility
Key points
History
ABO antigen expression and biochemistry
Pathophysiology
Settings of ABO incompatible reactions
Clinical management
Summary
Warm Autoimmune Hemolytic Anemia
Key points
Introduction
Diagnosis
Etiology
Associated conditions
Treatment
Summary/Discussion
Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Key points
Introduction
Cold agglutinins
Chronic cold agglutinin disease
Secondary cold agglutinin syndrome
Paroxysmal Cold Hemoglobinuria
Key points
Introduction
Mechanism of hemolysis
Prevalence and clinical presentation
Laboratory testing
Treatment
Summary
Paroxysmal Nocturnal Hemoglobinuria
Key points
Introduction
The pathophysiology of the complement dysregulation in paroxysmal nocturnal hemoglobinuria
The complement proteins in paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria as a hemolytic anemia
Paroxysmal nocturnal hemoglobinuria as a disease of marrow failure
Paroxysmal nocturnal hemoglobinuria as a disease of thrombosis
Paroxysmal nocturnal hemoglobinuria and consequences of nitric oxide
Diagnosis and classification of paroxysmal nocturnal hemoglobinuria
Current therapies for paroxysmal nocturnal hemoglobinuria directed against complement
Predictors of response to eculizumab therapy
Cure for paroxysmal nocturnal hemoglobinuria: hematopoietic stem cell transplantation
Future therapies for paroxysmal nocturnal hemoglobinuria directed against complement
Summary
Congenital CD59 Deficiency
Key points
Introduction
Function of CD59
Genetic basis of CD59 deficiency
Clinical symptoms of CD59 deficiency
Laboratory diagnosis of CD59 deficiency
CD59 as a blood group
CD59 deficiency and treatment
Summary
Ultralarge Von Willebrand Factor–Induced Platelet Clumping and Activation of the Alternative Complement Pathway in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndromes
Key points
Thrombotic microangiopathies (TMAs)
Overview of the thrombotic microangiopathies
Overview of the alternative complement pathway
Ultralarge von Willebrand factor multimers and initiation of the alternative complement pathway
Generation of terminal complement complexes
Ultralarge von Willebrand factor multimers and alternative complement pathway activation in the thrombotic microangiopathies
Ultralarge von Willebrand factor multimers, alternative complement pathway activation, and the formation of schistocytes
Summary
Shiga Toxin Associated Hemolytic Uremic Syndrome
Key points
Introduction
Epidemiology
Clinical course
Pathology
Pathogenesis
The complement system in Shiga toxin-associated hemolytic uremic syndrome pathogenesis
Mouse models
Treatment
Prognosis
Summary
Thrombotic Microangiopathy
Key points
Case presentation
Classification of thrombotic microangiopathy
Epidemiology
Complement pathway and regulation
Maintenance of endothelial health
Complement dysregulation associated with atypical hemolytic uremic syndrome
Complement–coagulation interface
Functional analysis of complement in management of atypical hemolytic uremic syndrome
Translating disease phenotyping to targeted therapy: challenges and opportunities
Summary
Current and Future Pharmacologic Complement Inhibitors
Key points
Introduction
Current complement inhibitors: eculizumab
Novel complement inhibitors
Summary
Index
Copyright
ELSEVIER
1600 John F. Kennedy Boulevard • Suite 1800 • Philadelphia, Pennsylvania, 19103-2899
http://www.theclinics.com
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA Volume 29, Number 3
June 2015 ISSN 0889-8588, ISBN 13: 978-0-323-38890-0
Editor: Jennifer Flynn-Briggs
Developmental Editor: Barbara Cohen-Kligerman
© 2015 Elsevier Inc. All rights reserved.
This periodical and the individual contributions contained in it are protected under copyright by Elsevier, and the following terms and conditions apply to their use:
Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ([phone] (UK)/([phone] (USA).
Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions ).
Electronic Storage or Usage
Permission of the Publisher is required to store or use electronically any material contained in this periodical, including any article or part of an article (please consult www.elsevier.com/permissions ). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.
Notice
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Hematology/Oncology Clinics (ISSN 0889-8588) is published bimonthly by Elsevier Inc., 360 Park Avenue South, NewYork, NY10010-1710. Months of issue are February, April, June, August, October, and December. Business and Editorial Offices: 1600 John F. Kennedy Blvd., Ste. 1800, Philadelphia, PA 19103–2899. Customer Service Office: 3251 Riverport Lane, Maryland Heights, MO63043. Periodicals postage paid at New York, NY and at additional mailing offices. Subscription prices are $385.00 per year (domestic individuals), $633.00 per year (domestic institutions), $190.00 per year (domestic students/residents), $440.00 per year (Canadian individuals), $783.00 per year (Canadian institutions) $520.00 per year (international individuals), $783.00 per year (international institutions), and $255.00 per year (international and Canadian students/residents). International air speed delivery is included in all Clinics subscription prices. All prices are subject to change without notice. POSTMASTER: Send address changes to Hematology/Oncology Clinics of North America , Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Customer Service (orders, claims, online, change of address): Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Tel: [phone] (U.S. and Canada); 314-447-8871 (outside U.S. and Canada). Fax: [phone]. E-mail: [e-mail] (for print support) ; [e-mail] (for online support) .
Reprints. For copies of 100 or more, of articles in this publication, please contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, New York 10010-1710; Tel.: [phone], Fax: [phone], E-mail: [e-mail] .
Hematology/Oncology Clinics of North America is covered in MEDLINE/PubMed (Index Medicus), EMBASE/Excerpta Medica, and BIOSIS.
Printed in the United States of America.
Contributors

Consulting Editors
GEORGE P. CANELLOS, MD
William Rosenberg Professor of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
H. FRANKLIN BUNN, MD
Professor of Medicine, Division of Hematology, Brigham and Women&